# Ponatinib for Advanced Medullary Thyroid Cancer

> **NCT01838642** · PHASE2 · TERMINATED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 3 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01838642
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Recruiting halted prematurely and will not resume. New study to open soon.
- **Last updated:** 2017-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838642, "Ponatinib for Advanced Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT01838642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*